Publications by authors named "Anastasia A Zackharova"
Pharmacokinetics and safety studies of innovative drugs is an essential part of drug development process. Previously we have developed a novel drug for intravenous administration (lyophilizate) containing modified endolysin LysECD7-SMAP that showed notable antibacterial effect in different animal models of systemic infections. Here we present data on pharmacokinetics of endolysin in mice after single and multiple injections.
View Article and Find Full Text PDFArticle Synopsis
- A limited number of innovative antibacterial agents are being developed to effectively target critical Gram-negative bacteria resistant to current treatments, with endolysins showing promise due to their unique action against these pathogens.
- The study uses a multidisciplinary approach including genetic engineering, structural analysis, and various formulations of the engineered endolysin LysECD7-SMAP, which are tested for effectiveness in preclinical models of infections such as sepsis and pneumonia.
- Results indicate that LysECD7-SMAP is effective against multiple drug-resistant bacteria, and in vivo studies confirm the efficacy of its formulated dosage forms, along with insights into how it interacts with bacterial cell walls.
Antibacterial therapy with phage-encoded endolysins or their modified derivatives with improved antibacterial, biochemical and pharmacokinetic properties is one of the most promising strategies that can supply existing antibacterial drugs array. Gram-negative bacteria-induced infections treatment is especially challenging because of rapidly spreading bacterial resistance. We have developed modified endolysin LysECD7-SMAP with a significant antibacterial activity and broad spectra of action against gram-negative bacteria.
View Article and Find Full Text PDF